According to the new regulations for domestic enterprises' overseas listing filing effective on March 31, 2023, the original pre-listing disclosure documents will become history for enterprises choosing H-shares listing in Hong Kong. The filing notice will replace the pre-listing disclosure documents for overseas listed companies.
On July 9th, 2024, the China Securities Regulatory Commission's International Cooperation Department issued a notice of filing for the overseas issuance and listing of Zhejiang Taimei Medical Technology Co., Ltd., and the 'Full Circulation' of domestically unlisted shares (Guohe Han [2024] No. 1435).
The specific content of the filing notice is as follows:
Zhejiang Taimei Medical Technology Co., Ltd.:
We have received the filing materials for the full circulation of your company's overseas-listed and unlisted shares in the domestic market. According to the provisions of the Securities Law of the People's Republic of China, the Measures for the Administration of the Issuance of Securities Abroad by Domestic Enterprises and the Listing Management of H-share Companies and the Guidelines for Applying for Full Circulation of Domestic Unlisted Shares by H-share Companies, etc., I hereby notify you of the filing matters as follows:
1. Your company plans to issue no more than 134,500,000 ordinary shares for overseas listing, and list them on the Hong Kong Stock Exchange.
2. A total of 37 shareholders of your company intend to convert their combined 174,813,533 domestically unlisted shares into shares listed overseas and trade them on the Hong Kong Stock Exchange. Shareholder names and conversion amounts are attached below.
3. From the date of issuance of this filing notice to the end of the overseas issuance and listing, if significant events occur in your company, you shall report through the filing management information system of the China Securities Regulatory Commission in accordance with relevant regulations on the issuance and listing of securities abroad by domestic enterprises.
4. Within 15 working days after your company completes the overseas issuance and listing, you should report the issuance and listing situation through the filing management information system of the China Securities Regulatory Commission. Your company should strictly comply with the relevant laws, regulations, and rules both domestically and abroad during the overseas issuance and listing and share conversion process.
5. If your company fails to complete the overseas issuance and listing and share conversion within 12 months from the date of issuance of this filing notice and plans to continue to promote it, the filing materials should be updated.
This filing notice only confirms information regarding the overseas issuance and listing and full circulation filing of the enterprise, and does not indicate that the China Securities Regulatory Commission has made a substantive judgment or guarantee on the investment value of the enterprise's securities or the investor's return, or that the China Securities Regulatory Commission has guaranteed or acknowledged the authenticity, accuracy, or completeness of the enterprise's filing materials.
Attachment: Shareholders' names and conversion quantities for full circulation.
International Cooperation Department of China Securities Regulatory Commission
July 9th, 2024.
Attachment:
No. | Shareholder name | Applied full circulation shares (shares) |
1 | Xinyu Taimei Xingmeng Enterprise Management Partnership (Limited Partnership) | 1,216,500 |
2 | Linzhi Tencent Investment Management Co., Ltd. | 11,220,205 |
3 | Jingwei Chuangteng (Hangzhou) Venture Capital Partnership (Limited Partnership) | 28,100,879 |
4 | Shanghai Chenxi Venture Capital Center (Limited Partnership) | 11,514,965 |
5 | Nanjing Kaiyuan Growth Venture Capital Partnership (Limited Partnership) | 11,473,611 |
6 | Suzhou Aurora Zhengyuan Venture Capital Partnership (Limited Partnership) | 10,139,955 |
7 | Suzhou Saifupuxin Medical Health Industry Investment Center (Limited Partnership) | 9,580,322 |
8 | Gongqing City Yuexi Investment Management Partnership (Limited Partnership) | 8,473,955 |
9 | Hangzhou Yangjian Investment Partnership (limited partnership) | 7,524,737 |
10 | Suzhou Xiangcheng District Ao Chuan Bangde Investment Partnership (limited partnership) | 7,885,411 |
11 | Nanjing Kaitai Entrepreneurship Investment Partnership (limited partnership) | 7,159,919 |
12 | Shanghai Yunfengrui Chi Investment Center (limited partnership) | 7,129,653 |
13 | Zhuhai Fuheng Investment Partnership (limited partnership) | 7,129,653 |
14 | Ningbo SoftBank Stable Growth Investment Partnership (limited partnership) | 6,957,645 |
15 | Suzhou Aurora Hongyuan Entrepreneurship Investment Partnership (limited partnership) | 5,790,494 |
16 | Suzhou Paiyi Entrepreneurship Investment Partnership (limited partnership) | 1,757,646 |
17 | Chengdu SoftBank Tian Investment Center (limited partnership) | 4,790,161 |
18 | Suzhou Kaifeng Taimei Entrepreneurship Investment Partnership (limited partnership) | 4,115,013 |
19 | Ivy (Changzhou) private equity investment fund partnership (limited partnership). | 3,199,833 |
20 | Shanghai Chenyu Investment Management Partnership (limited partnership). | 2,240,902 |
21 | Shanghai Kaifeng Zhide Venture Capital Partnership (limited partnership). | 2,138,716 |
22 | Suzhou Jingwei Chuangbo Investment Center (limited partnership). | 1,960,714 |
23 | Zhejiang Merchants Venture Capital Co., Ltd. | 1,609,427 |
24 | Nanjing Wuyuan Qixing Venture Capital Center (limited partnership). | 1,782,413 |
25 | Ningbo Jinjiao Langqiu Investment Partnership (limited partnership). | 1,734,167 |
26 | Shanghai Kaifeng Changyang Venture Capital Partnership (limited partnership). | 1,267,287 |
27 | Ningbo Xuri Xinzhu Investment Partnership (limited partnership). | 1,074,901 |
28 | Hangzhou Qizhen Future Innovation Equity Investment Partnership (limited partnership). | 960,061 |
29 | Li Shenjia | 809,097 |
30 | Shenzhen Futian Saifu Dynamic Equity Investment Fund Partnership (Limited Partnership) | 663,160 |
31 | Nanjing Saifu Hengzhun Entrepreneurship Investment Fund (Limited Partnership) | 654,470 |
32 | Huangshan Saifu Tourism and Cultural Industry Development Fund (Limited Partnership) | 654,470 |
33 | Jiaxing SoftBank Entrepreneurship Investment Partnership Enterprise (Limited Partnership) | 537,332 |
34 | Jiang Wenxin | 479,465 |
35 | Huzhou Kaifeng Housheng Enterprise Management Partnership Enterprise (General Partnership) | 373,190 |
36 | Beijing Qichuang Keyuan Equity Investment Fund Partnership Enterprise (Limited Partnership) | 356,602 |
37 | Gongqing City Jingqiong Investment Management Partnership Enterprise (Limited Partnership) | 356,602 |
Total | 174,813,533 | |
According to the listing rules of the HKEX, companies need to submit a "filing notice" at least 4 business days before the examination date, which means that Taimei Medical Technology has obtained the prerequisite for conducting the Hong Kong listing hearing, or will soon conduct the HKEX listing hearing.
Taimei Medical Technology submitted its prospectus to the HKEX on January 29th, 2024. Its main intermediaries for listing include Morgan Stanley and China International Capital Corporation as its joint sponsors, PwC as its auditor, Jingtian & Gongcheng and Mayer Brown as its Chinese and Hong Kong/US law firm respectively, Jingtian & Gongcheng and Guohao Law Firm as its Chinese lawyers for network security and data privacy protection and Zhong Lun and Cooley as its Chinese and Hong Kong/US law firms respectively for brokerages. Zhuaoshi Consultancy serves as its industry consultant.
Taimei Medical Technology, established in 2013, is a digital solution provider in research and development and marketing in the field of life sciences in China. It mainly provides cloud software and digital services through the digital collaboration platform - TrialOS and PharmaOS to promote clients' R&D and marketing activities in life sciences. According to Zhuo Shi Consultancy, Taimei Medical Technology is the largest digital solution provider in the field of research and development and marketing of life sciences in China in terms of revenue in 2022.
Taimei Medical prospectus link:
https://www1.hkexnews.hk/app/sehk/2024/106209/documents/sehk24012901131_c.pdf
